Management

Focused on new solutions for sickle cell disease

Focused on new solutions for sickle cell disease

Rahul D. Ballal, PhD, PhD

Chief Executive Officer

Dr. Ballal is CEO of Imara and has more than 15 years of life sciences experience in business development, strategic partnerships, venture capital, and company financing. He joined from Northern Biologics and Versant Ventures where he was Chief Business Officer and an Entrepreneur-in-Residence, respectively. At Northern, he built a first-in-class immuno-oncology portfolio, led a broad strategic partnership with Celgene, and managed several key functional roles at the executive level. At Versant, he negotiated foundational assets for existing portfolio and new companies, sourced several new deals, and participated in investment team activities. Previously, Dr. Ballal was Vice President, Business Development at Flexion Therapeutics, where he led several business development transactions, supported multiple functions during the initial public offering, and completed a key $175MM strategic partnership with Patheon UK, for dedicated commercial manufacturing. Prior to Flexion, he held business development and leadership positions at Novartis Venture Fund; Broad Institute of MIT and Harvard; and Redmind Inc. Dr. Ballal earned a Bachelor’s degree in Biology from Brown University, a Master’s degree in Bioinformatics from Johns Hopkins University and a Ph.D. in Biochemistry from Georgetown University. He is also a Kauffman Fellow.

Read More

Joe Datt, MD

Senior Vice President Clinical Development

Dr. Joe Datt, a board-certified pediatrician and neonatologist, brings 20 years of industry experience to Imara, most recently working in orphan drug development and rare diseases. He joined Imara from Orchard Therapeutics Limited in London where he was Global Head of Medical Affairs and Clinical Development, Immunology Franchise Lead. Prior to Orchard Therapeutics, he served as Global Senior Medical Affairs Director for BioMarin Europe Limited, where he was a core team leader for the company’s pipeline. Previously, he was Senior Medical Advisor, Neuroscience at Novartis Pharmaceuticals Limited. Dr. Datt earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of East Anglia. He is a review board committee member for the National Institute of Clinical Excellence (NICE) and is an educational supervisor and appraiser for the Faculty of Pharmaceutical Medicine at the Royal College of Physicians UK.

Read More

ShiYin Foo, MD, PhD, MMSC

Acting Chief Medical Officer

ShiYin Foo brings 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has expertise in a breadth of disease areas, including cardiorenal, immunology/inflammation and rare diseases, as well as an interest in novel and adaptive clinical trial designs.

Prior to joining Cydan, ShiYin was the Chief Medical Officer of Cardioxyl Pharmaceuticals and a translational medicine expert at the Novartis Institutes for Biomedical Research, where she was responsible for the establishment and development of multiple novel programs in heart failure and the cardiorenal space, including rare disease indications. ShiYin is the founder of Orchard Biomedical Consulting, which serves a variety of biotech and pharma partners in broad disease indications.

ShiYin received her MD and PhD in Immunology from Stanford University, and a MMSc in Clinical Science from the Clinical Investigator Training Program at Harvard Medical School. She was clinical faculty at the Massachusetts General Hospital and Harvard Medical School, and a dual Diplomate of the American Board of Internal Medicine and in Cardiology.

Read More

Siddharth Parulkar

Global Head of Clinical Operations

With more than a decade of drug development experience across multiple therapeutic areas, Mr. Siddharth Parulkar joins Imara from FujiFilm Pharmaceuticals, where he held the role of Global Program Manager. There he was responsible for the strategy, management and execution of early stage clinical development programs. Previously, he was Senior Clinical Project Manager at Leap Therapeutics, where he managed an early-stage clinical program for the treatment of cancer. Prior to Leap, he was Clinical Trial Manager at Tesaro, Inc. supporting multiple early- and late-stage clinical studies in oncology and immuno-oncology. Mr. Parulkar also held a number of clinical development and research positions at UCB Biosciences, GlaxoSmithKline Pharmaceuticals and Quintiles. Mr. Parulkar earned his Bachelor’s and Master’s degrees in Pharmacy from Rajiv Gandhi University of Health Sciences in India.

Read More